Heska Corp (NASDAQ:HSKA) has received an average rating of “Hold” from the ten ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation, one has assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $86.67.
Several research analysts have weighed in on the stock. Raymond James lowered shares of Heska from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 7th. They noted that the move was a valuation call. Canaccord Genuity reiterated a “buy” rating and issued a $105.00 price objective (up previously from $75.00) on shares of Heska in a research note on Wednesday, November 6th. Piper Jaffray Companies assumed coverage on shares of Heska in a research note on Wednesday, September 18th. They issued a “neutral” rating and a $68.00 price objective on the stock. Zacks Investment Research lowered shares of Heska from a “hold” rating to a “sell” rating in a research note on Friday, November 15th. Finally, BidaskClub upgraded shares of Heska from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, November 27th.
Shares of HSKA stock traded up $0.81 during trading hours on Wednesday, reaching $96.10. 71,199 shares of the stock traded hands, compared to its average volume of 88,808. Heska has a 1-year low of $62.47 and a 1-year high of $104.05. The business has a fifty day moving average price of $86.39 and a 200 day moving average price of $78.24. The company has a quick ratio of 6.80, a current ratio of 8.52 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $747.61 million, a PE ratio of 67.68 and a beta of 1.08.
Heska (NASDAQ:HSKA) last released its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.04) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.04). The firm had revenue of $31.24 million for the quarter, compared to analyst estimates of $30.44 million. Heska had a net margin of 3.15% and a return on equity of 3.17%. Research analysts expect that Heska will post 0.05 earnings per share for the current fiscal year.
Hedge funds have recently bought and sold shares of the business. Financial Gravity Wealth Inc. bought a new stake in Heska in the second quarter worth approximately $29,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Heska by 175.7% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 670 shares of the medical research company’s stock worth $47,000 after acquiring an additional 427 shares in the last quarter. Aperio Group LLC bought a new stake in Heska in the second quarter worth approximately $79,000. Quantamental Technologies LLC bought a new stake in Heska in the second quarter worth approximately $120,000. Finally, Bank of Montreal Can grew its position in Heska by 30.3% in the second quarter. Bank of Montreal Can now owns 2,162 shares of the medical research company’s stock worth $183,000 after acquiring an additional 503 shares in the last quarter. 97.92% of the stock is owned by institutional investors.
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.
See Also: Initial Coin Offering (ICO)
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.